<p>Long Non-Coding RNA <em>CASC19</em> Sponges microRNA-532 and Promotes Oncogenicity of Clear Cell Renal Cell Carcinoma by Increasing ETS1 Expression</p>

Abstract

Purpose: The long non-coding RNA cancer susceptibility 19 (CASC19) is recognized as an important regulator in gastric cancer, colorectal cancer, and non-small cell lung cancer. Nevertheless, to the best of our knowledge, the expression status and detailed roles of CASC19 in clear cell renal cell carcinoma (ccRCC) have not been elucidated. Hence, we aimed to determine CASC19 expression in ccRCC and investigate its roles in ccRCC oncogenicity. The molecular mechanisms underlying CASC19 functions in ccRCC were also determined. Methods: CASC19 expression was measured by using reverse transcription-quantitative polymerase chain reaction. The effects of CASC19 on ccRCC cell proliferation, colony formation, migration, and invasiveness in vitro, as well as on tumor growth in vivo, were examined by the MTT assay, colony formation assay, cell migration and invasiveness assays, and tumor xenograft in nude nice, respectively. Results: CASC19 was overexpressed in ccRCC tissues and cell lines. High expression of CASC19 was closely associated with unfavorable clinicopathological parameters and predicted negative clinical outcomes in patients with ccRCC. Knockdown of CASC19 decreased ccRCC cell proliferation, colony formation, migration, and invasiveness, as well as attenuated tumor growth in vivo. Mechanistically, CASC19 functioned as a competing endogenous RNA and upregulated the expression of ETS proto-oncogene 1 (ETS1) through sponging microRNA-532 (miR-532). Furthermore, rescue assays revealed that inhibiting miR-532 or restoring ETS1 expression partially abolished the impacts of CASC19 knockdown on ccRCC cells. Conclusion: The CASC19/miR-532/ETS1 regulatory pathway is crucial for the malignant manifestations of ccRCC, which makes it an attractive target for potential treatments of ccRCC.

<p>MiR-301a Promotes Cell Proliferation by Repressing PTEN in Renal Cell Carcinoma</p>

“…3 Furthermore, the 5-year survival rate of patients who diagnosed at the metastatic stage is less than 10%. 4 So there is an urgent need to better understand the molecular mechanism of the oncogenesis and progression of RCC to lay the foundation for finding early diagnosis and prognosis markers of RCC. Identification of key molecular events correlated with carcinogenesis and tumor progression would also facilitate the development of novel therapeutic targets and anti-RCC strategies.…”

Mechanism of tumor‑derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1

“…As previously, ETS1 as an oncogene is identified in close association with poor survival in multiple RCC specimens ( 27 ). Elevation of ETS1 via lncRNA-mediated regulation fosters the cell malignant behaviors and tumor growth in clear cell renal cell carcinoma (ccRCC) ( 39 ). Deregulated TFCP2L1 is intimately bound with various cancers, including ccRCC ( 40 ).…”

“…LncRNAs participate in epigenetic modification via chromosome remodeling, transcriptional regulation via transcription factor modulation and post-transcriptional regulation via mRNA alternative splicing respectively ( 41 ). LncRNA CASC19, as a competitive endogenous RNA, was found to upregulate ETS1 expression by sponging miR-532 ( 39 ), a participant of post-transcriptional regulation. The current study explored the direct interaction between RNA and certain transcription factors.…”

lncRNA CASC19 Contributes to Radioresistance of Nasopharyngeal Carcinoma by Promoting Autophagy via AMPK-mTOR Pathway

“…This lncRNA has been confirmed to be associated with the deterioration of human tumors of colorectal cancer [ 17 ] and gastric cancer [ 18 ]. Evidence suggests that the overexpression of CASC19 in Clear Cell Renal Cell Carcinoma (ccRCC) might play an oncogenic role in cancer progression [ 19 ], and knockdown of CASC19 suppressed cell proliferation, migration, and invasion in nonsmall cell lung carcinoma (NSCLC) [ 20 , 21 ]. In particular, CASC19 was significantly regulated in colon cancer cell lines after the treatment with different chemotherapeutic drugs [ 22 ].…”